Is Natalizumab available in China?

Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is also used to induce and maintain clinical response and remission in adult patients with moderately to severely active Crohn's disease who have evidence of inflammation that is inadequately responsive to or intolerant to conventional therapies and TNF-alpha inhibitors. Natalizumab should not be used in combination with immunosuppressants or TNF-alpha inhibitors. Natalizumab's original patent drug is not on the market in China and cannot be included in medical insurance. Therefore, the drug is temporarily unavailable in domestic hospitals and pharmacies.